Drug Coated Balloon-Only Strategy in De Novo Lesions of Large Coronary Vessels. (3rd February 2019)

• Record Type: Journal Article
• Authors: Rosenberg, Mark; Waliszewski, Matthias; Krackhardt, Florian; Chin, Kenneth; Wan Ahmad, Wan Azman; Caramanno, Giuseppe; Milazzo, Diego; Nuruddin, Amin Ariff; Liew, Houng Bang; Maskon, Oteh; Bento, Angela; Macia, Jean-Christophe; Frey, Norbert
• Other Names: Campo Gianluca Academic Editor.
• Is Part Of: Journal of interventional cardiology. Volume 2019(2019)
• Publication Date: 2019-02-03
• Subjects: Cardiology -- Periodicals; Heart -- Diseases -- Periodicals; 616.1206
• DOI: 10.1155/2019/6548696
• Languages: English
• ISSNs: 0896-4327

Abstract

Abstract : Objectives . We analyzed the efficacy of drug coated balloons (DCB) as a stand-alone-therapy in de novo lesions of large coronary arteries. DCBs seem to be an attractive alternative for the stent-free interventional treatment of de novo coronary artery disease (CAD). However, data regarding a DCB-only approach in de novo CAD are currently limited to vessels of small caliber. Methods . By means of propensity score (PS) matching 234 individuals with de novo CAD were identified with similar demographic characteristics. This patient population was stratified in a 1:1 fashion according to a reference vessel diameter cut-off of 2.75 mm in small and large vessel disease. The primary endpoint was the rate of clinically driven target lesion revascularization (TLR) at 9 months. Results . Patients with small vessel disease had an average reference diameter of 2.45 ± 0.23 mm, while the large vessel group averaged 3.16 ± 0.27 mm. Regarding 9-month major adverse cardiac event (MACE), 5.7% of the patients with small and 6.1% of the patients with large vessels had MACE (p=0.903). Analysis of the individual MACE components revealed a TLR rate of 3.8% in small and 1.0% in large vessels (p=0.200). Of note, no thrombotic events in the DCB treated coronary segments occurred in either group during the 9-month follow-up. Conclusions . Our data demonstrate for the first time that DCB-only PCI of de novo lesions in large coronary arteries (>2.75 mm) is safe and as effective. Interventional treatment for CAD without permanent or temporary scaffolding, demonstrated a similar efficacy for large and small vessels.